Article History
Received: 2 July 2017
Accepted: 31 January 2018
First Online: 13 February 2018
Compliance with ethical standards
:
: PI has served on scientific advisory boards for Biogen Idec, and has received funding for travel and/or speaker honoraria from Sanofi-Aventis, Biogen Idec, Teva and Novartis. MT has received honoraria for consultancy or speaking from Biogen, Sanofi-Aventis, Merck Serono, and Bayer-Schering and research grants from Merck Serono, Biogen and Novartis. DR declares no conflict of interest.
: The study was approved by the Ethics Committee of the University of Bari Medical School.
: Written informed consent was obtained by all patients before the start of natalizumab (NTZ).